# TriNetX

> TriNetX is a Cambridge-based health technology company connecting healthcare providers, life sciences organizations and academic researchers through a federated real-world clinical data network. Its software, licensed datasets and scientific consulting support study feasibility, trial site selection, observational research and drug safety. In June 2026 it reported more than 300 million patients across over 240 healthcare organizations.

- **Founded:** 2013
- **Headquarters:** Cambridge, United States
- **Founders:** Gadi Lachman (Founder and former President and CEO; board member)
- **Products:** TriNetX LIVE, TriNetX Dataworks, TriNetX Linked, EVIDEX, XetaBase
- **Notable:** Reported more than 300 million patients across 240+ healthcare organizations and 13,000+ sites in June 2026., The current data page lists 4,000+ peer-reviewed publications citing TriNetX; company-reported as observed October 1, 2026., Received the 2026 Clinical Trial Innovation Award from MedTech Breakthrough, according to its press-release listing.

## Products & services

- **TriNetX LIVE** — No-code cohort querying, feasibility analysis, site and investigator identification, outreach and real-world evidence analytics.
- **TriNetX Dataworks** — Licensed downloadable, row-level, de-identified EHR datasets for external analysis.
- **TriNetX Linked** — Links EHR data with medical and pharmacy claims, mortality and social determinants of health data.
- **EVIDEX** — Pharmacovigilance signal detection, evaluation and management software.
- **XetaBase** — Federated genomic and multimodal data management and analysis technology acquired with key Zetta Genomics assets.
- **TherapyMonitor** — European oncology data and analyses tailored to research objectives.
- **Scientific consulting** — Study design, epidemiology, real-world evidence research, external control arms and regulatory engagement support.
- **NLP-extracted Facts from Clinical Notes** — Makes clinical details in narrative notes available for cohort queries and licensed research datasets.

## Achievements

- Reported more than 300 million patients across 240+ healthcare organizations and 13,000+ sites in June 2026.
- The current data page lists 4,000+ peer-reviewed publications citing TriNetX; company-reported as observed October 1, 2026.
- Received the 2026 Clinical Trial Innovation Award from MedTech Breakthrough, according to its press-release listing.
- MetroHealth case study reports 20-30-fold growth in incoming trial opportunities.

## Latest updates

- **2026-09** — Published material on genomic integration in trial feasibility and a TriNetX/Parexel webinar on AI-assisted study design.
- **2026-06** — TriNetX LIVE network announced more than 300 million patients; most patients added from April 2025 to April 2026 came from international markets.
- **2026-05** — Announced the Clinical Trial Innovation Award from MedTech Breakthrough.
- **2026-04** — Announced Regeneron collaboration and planned investment up to US$200 million; separately acquired key Zetta Genomics assets.

## Links

- Website: https://trinetx.com/
- LinkedIn: https://www.linkedin.com/company/trinetx/
- Twitter/X: https://twitter.com/trinetx/

---

Profile page: https://yespress.io/trinetx
Published by YesPress — https://yespress.io
Last updated: 2026-10-01